Volume | 28 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
CytoDyn Inc (QB) | CYDY | OTCMarkets | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.23275 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
1 | 28 | - | 0.1456 - 0.48 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
08:00:01 | 28 | $ 0.22 | USD |
CytoDyn Inc (QB) Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
214.16M | 921.12M | 556.02M | 0 | -79.82M | -0.09 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
CytoDyn (QB) News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CYDY Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.1649 | 0.2341 | 0.15 | 0.1817736 | 3,962,899 | 0.06785 | 41.15% |
1 Month | 0.159 | 0.2341 | 0.15 | 0.1765082 | 1,960,234 | 0.07375 | 46.38% |
3 Months | 0.20 | 0.2341 | 0.1456 | 0.174668 | 1,348,260 | 0.03275 | 16.38% |
6 Months | 0.26 | 0.3103 | 0.1456 | 0.206261 | 1,486,912 | -0.02725 | -10.48% |
1 Year | 0.34 | 0.48 | 0.1456 | 0.2510891 | 1,669,582 | -0.10725 | -31.54% |
3 Years | 2.37 | 7.70 | 0.1456 | 1.74 | 2,486,080 | -2.14 | -90.18% |
5 Years | 0.5996 | 10.01 | 0.0552 | 2.32 | 2,683,236 | -0.36685 | -61.18% |
CytoDyn (QB) Description
CytoDyn is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells that is believed to play a role in numerous disease processes. CytoDyn is studying leronlimab in multiple therapeutic areas, including infectious disease, cancer, and autoimmune conditions. |